Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin vs ciprofloxacin for febrile neutropenia in hematologic patients
2024-520336-14-00Phase 3Authorised
- Sponsor
- FINBA
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Acute Leukaemia, febrile neutropenia (FN), neutropenia and 1 more comparing Fosfomycin with Ciprofloxacin (2 arms). Primary endpoints: Febrile neutropenia requiring antibacterial treatment, Time to Absolute Neutrophil Count >0.5x10^9/L and 2 more. Planned start Jan 2025; status: authorised.
02
Drugs
fosfomycinciprofloxacin
03
Conditions
Acute Leukaemiafebrile neutropenia (FN)neutropeniastem cell transplant (SCT)
Beyond the preview
Go deeper on 2024-520336-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520336-14-00.